Summary Innovative Targeting Solutions Inc (ITS) is an antibody generation company that discovers and develops novel human monoclonal antibody technologies.The company develops a next generation protein engineering platform that helps for the generation of fully human antibody and T cell receptor based therapeutics using its proprietary HuTARG technology.
Its HuTARG technology is a protein engineering platform that generates large repertoires of fully human antibodies or other protein-based drug modalities, in a mammalian cell host for the first time.It utilizes its technology to develop its pipeline programs such as agonists, rare epitopes, and complex membrane proteins for various therapeutic areas.
The company partners with pharmaceutical companies to identify specific target classes and therapeutic indications. ITS is headquartered in Vancouver, British Columbia, Canada.
Innovative Targeting Solutions Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
501 pages •
By Roots Analysis Private Ltd.
• Mar 2019
INTRODUCTION Chronic disorders, such as diabetes, cancer, heart disease, obesity, and certain types of mental health problems, are considered among the leading causes of death and disability across the globe. According to a report published by the Center for Managing Chronic Disease at the University of Michigan in 2018,...
The Global Oncology Partnering 2014-2019: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Oncology partnering deals Financial deal terms for headline, upfront and royalty...
Global Infectious Diseases Partnering 2014 to 2019 provides the full collection of Infectious Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Infectious Diseases partnering deals Financial deal terms for headline, upfront and royalty by stage of development Infectious...
The Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019: Deal trends, players, financials and forecasts report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains...
243 pages •
By Asia Market Information & Development Company
• Jul 2019
China’s demand for Biologics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019. The report brings you up-to-date...
Encephalomyelitis Global Clinical Trials Review, H1, 2019 Summary GlobalData’s clinical trial report, “Encephalomyelitis Global Clinical Trials Review, H1, 2019" provides an overview of Encephalomyelitis clinical trials scenario.This report provides top line data relating to the clinical trials on...
Encephalopathy Global Clinical Trials Review, H1, 2019 Summary GlobalData’s clinical trial report, “Encephalopathy Global Clinical Trials Review, H1, 2019" provides an overview of Encephalopathy clinical trials scenario.This report provides top line data relating to the clinical trials on Encephalopathy. Report...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.